{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:31Z","timestamp":1740144091518,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40262-024-01387-y","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T18:17:44Z","timestamp":1718993864000},"page":"901-915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants"],"prefix":"10.1007","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct04265781","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04802343","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xuening","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwa","family":"Haranaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2434-7164","authenticated-orcid":false,"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Reif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Francke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"issue":"12","key":"1387_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/bph.13957","volume":"175","author":"LP Bernier","year":"2018","unstructured":"Bernier LP, Ase AR, S\u00e9gu\u00e9la P. P2X receptor channels in chronic pain pathways. Br J Pharmacol. 2018;175(12):2219\u201330.","journal-title":"Br J Pharmacol"},{"issue":"Pt 2","key":"1387_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1113\/jphysiol.2003.048587","volume":"554","author":"RA North","year":"2004","unstructured":"North RA. P2X3 receptors and peripheral pain mechanisms. J Physiol. 2004;554(Pt 2):301\u20138.","journal-title":"J Physiol"},{"issue":"1700","key":"1387_CR3","doi-asserted-by":"publisher","first-page":"20150427","DOI":"10.1098\/rstb.2015.0427","volume":"371","author":"RA North","year":"2016","unstructured":"North RA. P2X receptors. Philos Trans R Soc Lond B Biol Sci. 2016;371(1700):20150427.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"Pt 2","key":"1387_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1113\/jphysiol.2005.088435","volume":"567","author":"DA Cockayne","year":"2005","unstructured":"Cockayne DA, Dunn PM, Zhong Y, Rong W, Hamilton SG, Knight GE, et al. P2X2 knockout mice and P2X2\/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol. 2005;567(Pt 2):621\u201339.","journal-title":"J Physiol"},{"key":"1387_CR5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3389\/fphar.2017.00661","volume":"8","author":"G Burnstock","year":"2017","unstructured":"Burnstock G. Purinergic signalling: therapeutic developments. Front Pharmacol. 2017;8:661.","journal-title":"Front Pharmacol"},{"key":"1387_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pupt.2017.06.009","volume":"47","author":"SJ Bonvini","year":"2017","unstructured":"Bonvini SJ, Belvisi MG. Cough and airway disease: the role of ion channels. Pulm Pharmacol Ther. 2017;47:21\u20138.","journal-title":"Pulm Pharmacol Ther"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.2147\/IJN.S146569","volume":"12","author":"M Yuan","year":"2017","unstructured":"Yuan M, Ding S, Meng T, Lu B, Shao S, Zhang X, et al. Effect of A-317491 delivered by glycolipid-like polymer micelles on endometriosis pain. Int J Nanomed. 2017;12:8171\u201383.","journal-title":"Int J Nanomed"},{"issue":"7","key":"1387_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/14656566.2018.1462795","volume":"19","author":"NM Ryan","year":"2018","unstructured":"Ryan NM, Vertigan AE, Birring SS. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Expert Opin Pharmacother. 2018;19(7):687\u2013711.","journal-title":"Expert Opin Pharmacother"},{"key":"1387_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fncel.2013.00236","volume":"7","author":"E Fabbretti","year":"2013","unstructured":"Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013;7:236.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"1387_CR10","doi-asserted-by":"publisher","first-page":"19877","DOI":"10.1038\/s41598-021-99177-0","volume":"11","author":"AJ Davenport","year":"2021","unstructured":"Davenport AJ, Neagoe I, Br\u00e4uer N, Koch M, Rotgeri A, Nagel J, et al. Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers. Sci Rep. 2021;11(1):19877.","journal-title":"Sci Rep"},{"issue":"10","key":"1387_CR11","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1111\/bcp.15358","volume":"88","author":"S Klein","year":"2022","unstructured":"Klein S, Gashaw I, Baumann S, Chang X, Hummel T, Thu\u00df U, et al. First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: tolerability, safety and pharmacokinetics. Br J Clin Pharmacol. 2022;88(10):4552\u201364.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1387_CR12","doi-asserted-by":"publisher","first-page":"2004240","DOI":"10.1183\/13993003.04240-2020","volume":"58","author":"A Morice","year":"2021","unstructured":"Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, et al. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021;58(5):2004240.","journal-title":"Eur Respir J"},{"issue":"3","key":"1387_CR13","doi-asserted-by":"publisher","first-page":"1901615","DOI":"10.1183\/13993003.01615-2019","volume":"55","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Butera P, Smith SA, Li Y, Xu ZJ, et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. 2020;55(3):1901615.","journal-title":"Eur Respir J"},{"issue":"8","key":"1387_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8(8):775\u201385.","journal-title":"Lancet Respir Med"},{"issue":"10328","key":"1387_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, et al. Efficacy and safety of gefapixant, a P2X(3) receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399(10328):909\u201323.","journal-title":"Lancet"},{"issue":"5753","key":"1387_CR16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1126\/science.1118435","volume":"310","author":"TE Finger","year":"2005","unstructured":"Finger TE, Danilova V, Barrows J, Bartel DL, Vigers AJ, Stone L, et al. ATP signaling is crucial for communication from taste buds to gustatory nerves. Science. 2005;310(5753):1495\u20139.","journal-title":"Science"},{"issue":"8","key":"1387_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40262-022-01126-1","volume":"61","author":"C Friedrich","year":"2022","unstructured":"Friedrich C, Francke K, Gashaw I, Scheerans C, Klein S, Fels L, et al. Safety, pharmacodynamics, and pharmacokinetics of P2X3 receptor antagonist eliapixant (BAY 1817080) in healthy subjects: double-blind randomized study. Clin Pharmacokinet. 2022;61(8):1143\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1387_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00408-023-00621-x","volume":"201","author":"PV Dicpinigaitis","year":"2023","unstructured":"Dicpinigaitis PV, Morice AH, Smith JA, Sher MR, Vaezi M, Guilleminault L, et al. Efficacy and safety of eliapixant in refractory chronic cough: the randomized, placebo-controlled phase 2b PAGANINI study. Lung. 2023;201(3):255\u201366.","journal-title":"Lung"},{"issue":"6","key":"1387_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","volume":"9","author":"O Olafuyi","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6): e00890.","journal-title":"Pharmacol Res Perspect"},{"key":"1387_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jpba.2016.03.052","volume":"126","author":"N Kadian","year":"2016","unstructured":"Kadian N, Raju KS, Rashid M, Malik MY, Taneja I, Wahajuddin M. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J Pharm Biomed Anal. 2016;126:83\u201397.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"1387_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s13318-022-00805-5","volume":"48","author":"K Francke","year":"2023","unstructured":"Francke K, Chattopadhyay N, Klein S, Rottmann A, Krickau D, van de Wetering J, et al. Preclinical and clinical pharmacokinetics and bioavailability in healthy volunteers of a novel formulation of the selective P2X3 receptor antagonist eliapixant. Eur J Drug Metab Pharmacokinet. 2023;48(1):75\u201387.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9974","key":"1387_CR22","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385(9974):1198\u2013205.","journal-title":"Lancet"},{"issue":"1","key":"1387_CR23","doi-asserted-by":"publisher","first-page":"1900439","DOI":"10.1183\/13993003.00439-2019","volume":"54","author":"AH Morice","year":"2019","unstructured":"Morice AH, Kitt MM, Ford AP, Tershakovec AM, Wu WC, Brindle K, et al. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur Respir J. 2019;54(1):1900439.","journal-title":"Eur Respir J"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01387-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01387-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01387-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:41:29Z","timestamp":1719988889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01387-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01387-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"22 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P.L., H.C., S.K., S.R., K.F., and C.F. are employees of Bayer AG; K.O. works for Bayer Yakuhin Ltd.; and X.L.,\u00a0M.H., and H.L. have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data underpinning this publication are made available in line with Bayer\u2019s commitment to the principles of responsible clinical trial data sharing adhered to by the European Federation of Pharmaceutical Industries and Associations and Pharmaceutical Research and the Manufacturers of America, in relation to the scope, time point, and process of data access. Bayer commits to sharing, upon request from qualified scientific and medical researchers, patient- and study-level clinical trial data and clinical\u00a0trial patient protocols for medicines and indications approved in the USA and European Union as a necessary requirement for legitimate research. This commitment applies to data on new medicines and indications that have been approved by the European Union and US regulatory agencies on or after January 1\u00a02014. Interested researchers can use  to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help to advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor section of the portal. Data access will be granted to anonymized patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"These studies were conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. The protocols were reviewed and approved by each study site\u2019s institutional review board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"All participants provided written, informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"S.R., K.F., C.F., and K.O. contributed to the design of the Japanese study. M.H. was the principal investigator of the Japanese study. P.L., H.C., S.R., K.F., and C.F. contributed to the design of the Chinese study. X.L. was the principal investigator and H.L. the sub-investigator of the Chinese study. S.K. carried out the statistical analysis in the Japanese and Chinese studies, as well as the post hoc inter-ethnic analysis. All authors interpreted the data, critically reviewed and revised the manuscript, and approved the final version for publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}